CUMBERLAND PHARMACEUTICALS INC
Datakwaliteit: 100%
CPIX
Nasdaq
Manufacturing
Chemicals
€ 3,09
▼
€ 0,02
(-0,64%)
Marktkapitalisatie: 46,22 M
Prijs
€ 3,09
Marktkapitalisatie
46,22 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—
Quick Summary
Belangrijkste Punten
Revenue grew 5,47% annually over 5 years — modest growth
Generating 4,83 M in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 12,10%
Capital efficient — spends only 0,22% of revenue on capex
Groei
Revenue Growth (5Y)
5,47%
Boven sectorgemiddelde (1,82%)
Revenue (1Y)17,57%
Earnings (1Y)N/A
FCF Growth (3Y)-8,80%
Kwaliteit
Return on Equity
-10,48%
Boven sectorgemiddelde (-53,53%)
ROIC-5,16%
Net Margin-6,37%
Op. Margin-6,27%
Veiligheid
Debt / Equity
N/A
Current Ratio1,23
Interest Coverage-5,63
Waardering
PE (TTM|NTM)
-16,30 | 22,07
Onder sectorgemiddelde (-1,48)
P/B Ratio1,77
EV/EBITDA22,92
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1366 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1366 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -16,3 | -1,5 |
| P/B | 1,8 | 1,6 |
| ROE % | -10,5 | -53,5 |
| Net Margin % | -6,4 | -41,5 |
| Rev Growth 5Y % | 5,5 | 1,8 |
| D/E | — | 0,3 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
Geen toekomstige schattingen beschikbaar
No quarterly estimates available
Winstverassingen
Laatste 4 kwartalen
| Kwartaal | Geschat WPA | Werkelijk WPA | Verrassing |
|---|---|---|---|
| Q22021 | -€ 0,07 | € 0,00 | +98,4% |
| Q12021 | -€ 0,07 | € 0,07 | +200,0% |
| Q42020 | -€ 0,01 | € 0,01 | +200,0% |
| Q32020 | -€ 0,07 | € 0,02 | +128,6% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 17,57% | Revenue Growth (3Y) | 6,10% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 5,47% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 44,52 M | Net Income (TTM) | -2,84 M |
| ROE | -10,48% | ROA | -4,24% |
| Gross Margin | N/A | Operating Margin | -6,27% |
| Net Margin | -6,37% | Free Cash Flow (TTM) | 4,83 M |
| ROIC | -5,16% | FCF Growth (3Y) | -8,80% |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 1,23 |
| Interest Coverage | -5,63 | Asset Turnover | 0,67 |
| Working Capital | 5,63 M | Tangible Book Value | 10,20 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -16,30 | Forward P/E | 22,07 |
| P/B Ratio | 1,77 | P/S Ratio | 1,04 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | 22,92 | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | 4,53% |
| FCF Yield | 10,46% | ||
| Market Cap | 46,22 M | Enterprise Value | 31,02 M |
| Per Share | |||
| EPS (Diluted TTM) | -0,19 | Revenue / Share | 2,98 |
| FCF / Share | 0,32 | OCF / Share | 0,33 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 0,22% | FCF Conversion | -170,47% |
| SBC-Adj. FCF | 4,52 M | Growth Momentum | 12,10 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 44,52 M | 37,87 M | 39,55 M | 42,01 M | 35,99 M |
| Net Income | -2,84 M | -6,48 M | -6,28 M | -5,57 M | -3,51 M |
| EPS (Diluted) | -0,19 | -0,46 | -0,44 | -0,38 | -0,24 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -2,79 M | -6,43 M | -9,55 M | -5,70 M | -7,68 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 5,57 M | 4,82 M | 5,83 M | 6,69 M | 5,68 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 4,15 M | 4,90 M | 4,94 M | 5,33 M | 4,61 M |
| Interest Expense | 495.990,0 | 605.508,0 | 667.861,0 | 585.995,0 | 98.031,0 |
| Income Tax | 40.256,0 | -22.669,0 | 45.769,0 | 68.850,0 | 34.891,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 76,82 M | 75,58 M | 81,78 M | 92,93 M | 84,46 M |
| Total Liabilities | 52,28 M | 53,04 M | 52,52 M | 56,95 M | 41,86 M |
| Shareholders' Equity | 24,88 M | 22,85 M | 29,60 M | 36,27 M | 42,81 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 11,44 M | 17,96 M | 18,32 M | 19,76 M | 27,04 M |
| Current Assets | 37,06 M | 36,45 M | 35,71 M | 45,87 M | 45,69 M |
| Current Liabilities | 36,74 M | 31,62 M | 27,98 M | 28,58 M | 19,28 M |
{"event":"ticker_viewed","properties":{"ticker":"CPIX","listing_kind":"stock","pathname":"/stocks/cpix","exchange":"Nasdaq","country":"US"}}
